Burger King President Says GLP-1s Will Have 'Impact' on Industry

Burger King is preparing for a fast-food landscape where customers may still crave convenience and familiar flavors, but in smaller portions. Tom Curtis, the company’s president for the U.S. and Canada, told NBC News that the rise of GLP-1 weight-loss medications is poised to reshape the restaurant business in a major way. In response, Burger King has begun experimenting with options such as Whopper Bites and protein-focused bowls designed for changing eating habits.

The shift is already showing up in the numbers. According to a Gallup survey, 11% of American adults are currently using a GLP-1 drug, a figure that has grown to nearly four times what it was two years ago. The National Restaurant Association also found that almost half of GLP-1 users say they are eating out less. JPMorgan has projected that these medications could reduce annual food and beverage industry sales by $30 billion to $55 billion by 2030.

Still, Curtis said Burger King is not making a dramatic menu overhaul just yet, especially with the Whopper continuing to perform well. For now, the burger chain is focusing on its $2 billion “Reclaim the Flame” comeback strategy, which helped lift same-store sales by 5.8% in the most recent quarter after a 1.1% drop during the prior year.

Burger King is looking ahead to a future in which fast-food fans may want the same speed and taste, but with lighter portions and more flexible choices. Curtis told NBC News that the growing use of GLP-1 medications could have a significant effect across the restaurant industry. As part of that adjustment, the chain is testing smaller-format items like Whopper Bites along with bowls that put protein at the center of the meal.

The potential impact on restaurants is substantial. Gallup data shows that 11% of U.S. adults are now taking GLP-1 medications, nearly quadrupling over the past two years. Meanwhile, nearly half of users surveyed by the National Restaurant Association said they have reduced how often they dine out. Analysts at JPMorgan estimate that GLP-1 drugs could cut between $30 billion and $55 billion from yearly food and beverage revenue by the end of the decade.

For the moment, Burger King is taking a measured approach rather than immediately redesigning its entire menu. Curtis noted that demand for the Whopper remains healthy, giving the brand room to move carefully. The company is also continuing to build on its $2 billion “Reclaim the Flame” initiative, a turnaround plan credited with helping same-store sales climb 5.8% last quarter after falling 1.1% a year earlier.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

ESPN Layoffs: Key Staff and Talent Impacted by Major Cuts

Topline ESPN’s latest round of layoffs, which on Tuesday hit several well-known…

The 5-Day Time Audit That Helps Entrepreneurs Avoid Burnout

Opinions expressed by Entrepreneur contributors are their own. Key Takeaways Every business…

Vermont Chatbot Therapy Law Sparks Fears Over AI Advice

Vermont’s new AI mental health law spotlights a growing concern: could therapists…

12 Must-Have Funds for Rock-Solid Monthly Investment Income

Income investing has slipped out of the spotlight in recent years, overshadowed…

London Stock Exchange Overnight Trading: Investor Guide

The London Stock Exchange has announced plans for a new extended-hours trading…